Rockport Wealth LLC Sells 2,187 Shares of Intuitive Surgical, Inc. $ISRG

Rockport Wealth LLC lowered its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.8% in the first quarter, HoldingsChannel reports. The firm owned 54,873 shares of the medical equipment provider’s stock after selling 2,187 shares during the quarter. Intuitive Surgical makes up approximately 4.6% of Rockport Wealth LLC’s holdings, making the stock its 6th largest holding. Rockport Wealth LLC’s holdings in Intuitive Surgical were worth $25,292,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ISRG. Newbridge Financial Services Group Inc. boosted its holdings in shares of Intuitive Surgical by 300.0% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 44 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 33 shares during the period. Holos Integrated Wealth LLC bought a new stake in Intuitive Surgical in the 4th quarter valued at about $25,000. Olistico Wealth LLC bought a new stake in shares of Intuitive Surgical during the fourth quarter valued at approximately $28,000. Laurel Wealth Advisors LLC bought a new stake in Intuitive Surgical during the 4th quarter valued at $31,000. Finally, Turning Point Benefit Group Inc. lifted its holdings in Intuitive Surgical by 833.3% in the fourth quarter. Turning Point Benefit Group Inc. now owns 56 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 50 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Insider Transactions at Intuitive Surgical

In related news, EVP Gary Loeb sold 400 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total value of $169,656.00. Following the completion of the sale, the executive vice president directly owned 5,720 shares in the company, valued at approximately $2,426,080.80. The trade was a 6.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 119 shares of the stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $463.50, for a total value of $55,156.50. Following the transaction, the director owned 120 shares in the company, valued at approximately $55,620. This trade represents a 49.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 7,169 shares of company stock worth $3,059,135. 0.60% of the stock is owned by corporate insiders.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: BMO Capital initiated coverage with an Outperform rating, adding to the case that Intuitive Surgical can continue to defend its leadership in robotic surgery. BMO Capital Starts Intuitive Surgical (ISRG) at Outperform
• Positive Sentiment: Several articles note that ISRG heads into earnings with strong procedure momentum, da Vinci 5 adoption, and a history of beating estimates, which supports hopes for another solid quarter. Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now?
• Positive Sentiment: Intuitive Surgical’s Ion lung biopsy study is approaching a data readout, highlighting a potential new growth avenue beyond core robotic surgery. Intuitive Surgical’s Ion Lung Biopsy Study Nears Data Readout, Eyeing New Growth in Diagnostics
• Neutral Sentiment: Commentary around Intuitive Surgical’s leadership versus rising global competition is mixed: the company is using AI features and a broad ecosystem to defend share, but competition remains a watch item. Can ISRG Defend Its Leadership as Global Competition Intensifies?
• Neutral Sentiment: Some coverage frames the move as a pre-earnings repositioning event, with investors weighing recent analyst target cuts, margin pressure from tariffs, and broader medical-device weakness more than any new company-specific setback. Intuitive Surgical Falls as Target Cut and Pre-Earnings Jitters Weigh on Shares

Intuitive Surgical Trading Up 2.5%

Intuitive Surgical stock opened at $388.97 on Thursday. The company has a market capitalization of $137.76 billion, a P/E ratio of 47.15, a P/E/G ratio of 3.09 and a beta of 1.46. The firm’s fifty day simple moving average is $418.39 and its 200-day simple moving average is $469.98. Intuitive Surgical, Inc. has a 1-year low of $378.50 and a 1-year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.08 by $0.42. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. Intuitive Surgical’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.81 EPS. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Royal Bank Of Canada cut their price objective on Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating for the company in a report on Monday. Evercore set a $430.00 price objective on shares of Intuitive Surgical in a research report on Monday, July 6th. Robert W. Baird upped their target price on Intuitive Surgical from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. BMO Capital Markets began coverage on shares of Intuitive Surgical in a report on Wednesday, July 8th. They set an “outperform” rating and a $518.00 price target on the stock. Finally, Leerink Partners dropped their target price on Intuitive Surgical from $622.00 to $573.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $565.31.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.